Dávila, Ignacio
Puente, Luis
Quirce, Santiago
Arismendi, Ebymar
Díaz-Palacios, Miguel
Pereira-Vega, Antonio
de Diego, Alfredo
Rodriguez-Hermosa, Juan Luis
Cea-Calvo, Luis
Sánchez-Jareño, Marta
López-Cotarelo, Pilar
Domingo, Christian
Funding for this research was provided by:
MSD Spain
Article History
Received: 3 March 2023
Accepted: 18 April 2023
First Online: 9 May 2023
Declarations
:
: Ignacio Dávila: Consulting fees from Allergy Therapeutics, AstraZeneca, GSK, MSD, Novartis, and Sanofi. Lectures for Allergy Therapeutics, AstraZeneca, Chiesi, Diater, GSK, LETI, Novartis, and Sanofi. Grants to institution from ISCIII, Junta de Castilla de León, and Thermofisher. Luis Puente: No conflict of interest declared. Santiago Quirce has received speaking, lecture and consulting fees from Allergy Therapeutics, AstraZeneca, GSK, Mundipharma, Novartis, Sanofi, and Teva. Ebymar Arismendi: No conflict of interest declared. Miguel Díaz-Palacios: No conflict of interest declared. Antonio Pereira-Vega: No conflict of interest declared. Alfredo de Diego: No conflict of interest declared. Juan Luis Rodríguez-Hermosa: Consulting fees from Bial and Grifols; payments for lectures including service on speakers’ bureaus from Boehringer, Grifols, GSK, and Zambon. Christian Domingo-Ribas: No conflict of interest declared. Luis Cea-Calvo, Marta Sánchez-Jareño and Pilar López-Cotarelo are full-time employees at MSD, Spain.
: The study was performed in accordance with Good Pharmacoepidemiology Practice standards and the principles of the Declaration of Helsinki.